AstraZeneca made $10bn offer for obesity drugmaker Rhythm, sources say
AstraZeneca (AZN) made an offer of about $10bn to acquire obesity drugmaker Rhythm Pharmaceuticals (RYTM), according to three people familiar with the matter.
AstraZeneca (AZN) made an offer of about $10bn to acquire obesity drugmaker Rhythm Pharmaceuticals (RYTM), according to three people familiar with the matter.
Surgery Partners (SGRY) will be taken private by HealthSpan Partners, an affiliate of nonprofit hospital system Bon Secours Mercy Health, in a deal valued at about $5.7bn including debt. Shares in the outpatient surgery operator rose 46…
Zealand Pharma (ZELA) has partnered with US biotech Generate Biomedicines (GENB) to develop protein-based treatments for obesity and other metabolic diseases using artificial intelligence, in a deal worth up to $1.2bn.
AstraZeneca (AZN) has teamed up with artificial intelligence biotech insitro to discover and develop treatments for liver and heart conditions that have proved hard to treat, the British drugmaker said.
Swiss skincare company Galderma (GALD) has agreed to acquire US group ZO Skin Health for an enterprise value of $1.5bn, confirming an earlier Reuters report. The purchase of the Irvine, California-based company is Galderma's largest since…
Steris (STE) will buy privately held Xodus Medical for $2.1bn, adding surgical products designed to improve safety for patients and operating-room staff to its healthcare consumables business.
Viatris (VTRS) has agreed to buy Pacira BioSciences (PCRX) for $1.65bn in cash. The deal adds two non-opioid pain treatments to its portfolio as the drugmaker tries to build out higher-value branded medicines beyond its core generics…
CSL (CSL.AX) has agreed to co-develop and co-promote an experimental treatment for rare kidney and liver diseases with Swiss drugmaker Alentis Therapeutics, in a deal worth up to $1.6bn, excluding development funding.
Sanofi (SAN) and Regeneron (REGN) have agreed to develop four new drugs together in a deal worth up to $8bn and to settle prior litigation, a move analysts said signals a reset of their strained partnership and an early victory for…
Novartis (NOVN) has agreed a licensing deal worth up to $7.8bn with China's Abogen to develop therapies based on messenger RNA, underscoring the Swiss drugmaker's growing interest in an emerging class of treatments.
Roche (RHHBY) has agreed a deal with Atavistik Bio worth almost $2bn, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases.
InnoCare Pharma (688428.SS) has signed a research collaboration and licensing agreement with Eli Lilly (LLY) worth up to about $3.35bn, the Chinese drugmaker announced.